Phaseline

Companies › Alvotech Swiss

Alvotech Swiss: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology, Ophthalmology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AVT29
VEGF-A inhibitor (proposed aflibercept HD biosimilar)
VEGFAPhase 3Diabetic Macular EdemaJul 2027
AVT32-DRL_PB
PD-1 inhibitor (pembrolizumab biosimilar)
PDCD1Phase 1MelanomaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07489131AVT29Phase 3Diabetic Macular EdemaOphthalmologyJul 2027
NCT07475572AVT32-DRL_PBPhase 1MelanomaOncologyOct 2027

From the company's SEC filings

Complete response letters from FDA

Targets

PDCD1 (1) VEGFA (1)

Companies with the same targets

Akeso Roche Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Regeneron Pharmaceuticals Sichuan Baili Pharmaceutical Jiangsu Simcere Pharmaceutical Shenyang Sunshine Pharmaceutical AbbVie

Companies built like this

Samsung Bioepis Binhui Biopharmaceutical Shanghai Juncell Therapeutics CrystalGenomics Intra-IMMUSG Pte

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.